Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice


Join us to learn more about how to mitigate the risk of adventitious agents in the medicinal product manfacturing process.


May 23, 2019, 22:00


May 23, 2019, 22:00



Together with product efficacy, product safety is an essential characteristic of any medicinal product, including cell and gene therapy (C&GT) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc.) pose a constant risk to these biologics, and, as such they may impact product and patient safety directly. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C&GT product manufacturing process to mitigate the risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate risk while providing a high degree of product safety by design.

Date/Time: 24th May 2019 | 10.00 am EDT


Mark Plavsic, Chief Technology Officer at Lysogene
Dr. Archie Lovatt, Biosafety Scientific Director, SGS